Guru Sonpavde, MD

Guru P. Sonpavde, MD serves as the Medical Director of Genitourinary (GU) Oncology and the Phase I Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research () at the AdventHealth Cancer Institute (List of active Phase I trials here: Search for: In Celebration, FL, Recruiting studies, Phase: 1 | Card Results | ClinicalTrials.gov). Previously, he was Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School from 2017-2022, GU Oncology Director and Associate Professor of Medicine at the University of Alabama at Birmingham from 2012 to 2017 and practiced from 2004 to 2012 at Texas Oncology. Dr. Sonpavde’s focus is drug development and translational research to cure GU cancers, which have led to approximately 500 publications (sonpavde - Search Results - PubMed). In addition to his expertise in Urologic Medical Oncology, he also conducts Phase I clinical trials. He is a member of Southwest Oncology Group, Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee. He was cited in TIME magazine regarding his participation in clinical trials in August 2022 (Clinical Trials for Bladder Cancer | TIME).”